NCT05797805: An ongoing trial by Iterion Therapeutics
This trial is ongoing. It must report results 1 year, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05797805 |
|---|---|
| Title | A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 13, 2023 |
| Completion date | May 31, 2026 |
| Required reporting date | May 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |